Nuvation Bio Inc
NUVB_t0.209USD
-0.001-0.57%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Más Datos de Nuvation Bio Inc Compañía
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Información de la empresa
Símbolo de cotizaciónNUVB_t
Nombre de la empresaNuvation Bio Inc
Fecha de salida a bolsaJul 01, 2020
Director ejecutivoDr. David T. Hung, M.D.
Número de empleados- -
Tipo de seguridad- -
Fin del año fiscal- -
Dirección357 Tehama Street, Floor 3
CiudadSAN FRANCISCO
Bolsa de valores- -
PaísUnited States of America
Código postal94103
Teléfono14157543517
Sitio Webhttps://www.nuvationbio.com/
Símbolo de cotizaciónNUVB_t
Fecha de salida a bolsaJul 01, 2020
Director ejecutivoDr. David T. Hung, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. Joe Rayne
Mr. Joe Rayne
Investor Relations
Investor Relations
--
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
--
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
--
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Gary Hattersley, Ph.D.
Dr. Gary Hattersley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
--
--
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
--
--
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. Joe Rayne
Mr. Joe Rayne
Investor Relations
Investor Relations
--
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
--
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
--
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Gary Hattersley, Ph.D.
Dr. Gary Hattersley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 28 de feb
Actualizado: vie., 28 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Other
100.00%
Accionistas
Accionistas
Proporción
Other
100.00%
Tipos de accionistas
Accionistas
Proporción
Other
100.00%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
30
31.74M
0.00%
+26.49M
2025Q1
30
31.74M
0.00%
+26.49M
2024Q4
31
4.90M
0.00%
-302.14K
2024Q3
30
4.86M
0.00%
-182.30K
2024Q2
31
4.71M
0.00%
+261.45K
2024Q1
29
4.01M
0.00%
-276.84K
2023Q4
27
4.00M
0.00%
-301.37K
2023Q3
26
4.18M
0.00%
-276.64K
2023Q2
26
4.34M
0.00%
-268.70K
2023Q1
26
4.49M
0.00%
-128.42K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Rock Springs Capital Management LP
134.03K
0%
--
--
Mar 31, 2025
Samsara BioCapital, LLC
133.33K
0%
--
--
Mar 31, 2025
Greenlight Capital, Inc.
100.00K
0%
--
--
Mar 31, 2025
Acuta Capital Partners, LLC
90.83K
0%
--
--
Mar 31, 2025
Citadel Advisors LLC
73.55K
0%
-408.00
-0.55%
Mar 31, 2025
Logos Global Management LP
66.67K
0%
--
--
Mar 31, 2025
Victory Capital Management Inc.
58.11K
0%
-440.00
-0.75%
Mar 31, 2025
Intellectus Partners, LLC
22.40K
0%
--
--
Mar 31, 2025
Boxer Capital Management, LLC
266.67K
0%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
963.33K
0%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
